MedTrace Logo

MEsenchymal StEm Cells for Multiple Sclerosis

NCT01854957 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-05-16

No results posted yet for this study

Summary

A double-blind, randomized, cross-over phase I/II study to evaluate the safety and the efficacy of the intravenous administration of autologous Mesenchymal Stem Cells (MSC) to patients with active multiple sclerosis (MS) resistant to currently available therapies.

Conditions

Interventions

BIOLOGICAL

Autologous Mesenchymal Stem Cells

Single dose of 1-2 x 1000000 cells/Kg body weight

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Integrata Verona

    collaborator OTHER

  • Ospedale San Raffaele

    collaborator OTHER

  • Antonio Uccelli

    lead OTHER

Principal Investigators

  • Giancarlo Comi, MD · Ospedale San Raffaele

  • Bruno Bonetti, MD · Azienda Ospedaliera Universitaria Integrata di Verona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-07-31
Completion
2014-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01854957 on ClinicalTrials.gov